Nevertheless, there is accumulating preclinical evidence to demonstrate that both Chk1 and Wee1 inhibition are able to radiosensitise cells from various different tumours both in vitro and in vivo, which supports their potential to be exploited further in the clinic for the benefit of cancer patients. The gene discussed is CHEK1; the disease is neoplasm.